Table 1 Demographic and clinical data of both groups of patients: active mouthwash (AM) and non-active mouthwash (NAM) groups.

From: Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19: randomised trial

 

Group

p-value

NAM

AM

Mean (SD)

Median (min–max)

mean (SD)

Median (min–max)

Age (years)

48.4 (11.4)

47.0 (27.0–70.0)

59.1 (13.0)

59.0 (32.0–78.0)

10.0069

Number of comorbidities

1.4 (1.4)

1.0 (0.0–4.0)

1.6 (1.3)

1.5 (0.0–5.0)

10.6481

Duration of symptoms prior to hospitalization (days)

4.3 (2.1)

4.0 (1.0–9.0)

5.3 (1.9)

6.0 (1.0–9.0)

10.1238

 

n

%

n

%

 

Males

13

61.9%

13

65.0%

20.8370

Age > 60 y

4

19.0%

10

50.0%

20.0367

Presence of comorbidities

14

66.7%

16

80.0%

20.3355

  1. 1Mann Whitney-U; 2 Chi-square; SD standard deviation.